Smoking and schizophrenia: Where is the biological connection?

Turk Psikiyatri Dergisi

Volumn 17, Issue 1, 2006, Pages

  Üneri, Özden ^a   Tural, Ümit ^a   Çakin Memik, Nursu ^a  

^a NONE

Author keywords

Dopamine; Nicotine; Nicotinic acetylcholine receptor; Schizophrenia; Smoking

Indexed keywords

EID: 33646584502     PISSN: 13002163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Adler LE, Hoffer LD, Wiser A et al. (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry, 150: 1856-1861.
2. Adler LE, Olincy A, Waldo M et al. (1998) Smoking, sensory gating and nicotinic receptors. Schizophr Bull, 24: 189-202.
3. Akvardar Y, Tümüklü M, Kivircik B et al. (2001) Usage prevalence of smoking, alcohol and other drugs in schizophrenia. 37th National Psychiatry Congress, Abstract Book 124.
4. Akvardar Y, Demiral Y, Ergör G et al, (2003) Substance use in a sample of Turkish medical students. Drug Alcohol Depend, 72: 117-121.
5. Alkondon M, Pereira EF, Barbosa CT et al. (1997) Neuronal nicotinic acetylcholine receptor activation modulates gamma-aminobutyric acid release from CA1 neurons of rat hippocampal slices. J Pharmacol Exp Ther, 283: 1396-1411.
6. Allebeck P, Wistedt B (1986) Mortality in schizophrenia. Arch Gen Psychiatry, 43: 650-653.
7. Alptekin K, Mete L, Yazici K et al. (2002) Comorbid substance abuse and smoking in Turkish patients with schizophrenia. Schizophr Res, 53 (Suppl. XIth Biennial Winter Workshop on Schizophrenia): 224.
8. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (Translated and Edited by: E Köroǧlu) Hekirnler Yayιn Birliǧi, Ankara, 1995.
9. Araki H, Suemaru K, Gomita Y (2002) Neuronal nicotinic receptor and psychiatric disorders: Functional and behavioral effects of nicotine. Jpn J Pharmacol, 88: 133-138.
10. Bahk JY, Li S, Park MS et al. (2002) Dopamine D1 and D2 receptor mRNA up-regulation in the caudate-putamen and nucleus accumbens of rat brains by smoking. Prog Neuropsychopharmacol Biol Psychiatry, 26: 1095-1104.
11. Baron JA (1986) Cigarette smoking and Parkinson's disease. Neurology, 36: 1490-1496.
12. Benowitz NL (1996) Pharmacology of nicotine, addiction and therapeutics. Annu Rev Pharmacol Toxicol, 36: 597-613.
13. Beratis S, Katrivanou A, Gourzis P (2001) Factors affecting smoking in schizophrenia. Compr Psychiatry, 42: 393-402.
14. Bozikas VP, Papakosta M, Niopas I et al. (2004) Smoking impact on CY1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol 14: 39-44.
15. Breslau N, Scott P. Kessler R (2004) Psychiatric disorder and stages of smoking. Biol Psychiatry, 55: 69-76.
16. Brody AL, Mandelkern MA, Jarvick ME et al. (2004) Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol Psychiatry, 55: 77-84.
17. Brown S, Inksip H, Barraclough B (2000) Causes of the excess mortality of schizophrenia. Br J Psychiatry, 177: 212-217.
18. Buda M, Tsuang MT, Fleming JA (1988) Causes of death in DSM-III schizophrenics and other psychotics (atypical group). Arch Gen Psychiatry, 45: 283-285.
19. Changeux JP, Bertrand D, Corringer PJ et al. (1998) Brain nicotinic receptors: structure and regulation, role in learning and reinforcements. Brain Res Rev, 26:198-216.
20. Chou KR, Chen R, Lee JF et al. (2004) The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud, 41: 321-330.
21. Corrigall WA, Franklin KB, Coen KM et al. (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl), 107: 285-289.
22. Corrigall WA, Coen KM, Adamson K (1994) Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res, 653: 278-284.
23. Covey LS, Glassman AH, Stetner F (1997) Major depression following smoking cessation. Am J Psychiatry, 154: 263-265.
24. Çilli AS, Kaya N (2003) Nicotine Dependence and Psychiatric Comorbidity Among University Students. Turkish Journal of Psychiatry, 14: 42-49.
25. Dalack GW, Healy DJ, Meador-Woodruff JH (1998) Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry, 155: 1490-1501.
26. Dani JA, Heinemann S (1996) Molecular aspects of nicotine abuse. Neuron, 16: 905-908.
27. de Leon J, Dadvand M, Canuso C et al. (1995) Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry, 152: 453-455.
28. de Leon J, Tracy J. McCann E et al. (2002) Schizophrenia and tobacco smoking: a replication study in other US psychiatric hospital. Schizophr Res, 56: 55-65.
29. Dilbaz N, Apaydin L (2002) Aspects of smoking, quitting frequency and smoking behavior between nurses working in an education and research hospital. Jornal of Dependence, 3: 73-83.
30. Dolan SL, Sacco KA, Temrine A et al. (2004) Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr Res, 70: 263-275.
31. Domino EF, Minoshima S, Guthrie SK et al. (2000) Effects of nicotine on regional cerebral glucose metabolism in awake resting tobacco smokers. Neuroscience, 101: 277-282.
32. Fagerström KO, Pomerleau O, Giordani B et al. (1994) Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl), 116: 117-119.
33. Fagerstrom KO, Hughes JR (2002) Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. Nicotine Tob Res, 4 (Suppl 2): S73-79.
34. Fowler JS, Volkow ND, Wang GJ et al. (1996) Inhibition of monoamine oxidase B in the brain of smokers, Nature, 379: 733-738.
35. Fowler JS, Volkow ND, Wang GJ et al.(1998) Neuropharmacological actions of cigarette smoke: Brain monoamineoxidase B (MAO B) inhibition. J Addict Dis, 17: 23-34.
36. Freedman R, Wetmore C, Stromberg I et al. (1993). Bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effects on growth factor expression. J Neurosci, 13: 1965-1975.
37. Freedman R, Hall M, Adler LE et al. (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry, 38: 22-33.
38. Freedman R, Coon H, Myles-Worsley et al, (1997) Linkage of neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA, 94: 587-592.
39. Freedman R, Leonard S, Gault JM et al (2001) Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha 7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Gen, 105: 20-22.
40. Goodman J (1995) Tobacco in history: The cultures of dependency. Routledge, New York, s.3-19.
41. Gray R, Rajan AS, Radcliffe KA et al. (1996) Hippocampal synaptic transmission enhanced by low concentiations of nicotine. Nature, 383: 713-716.
42. Griffith JM, O'Neill EJ, Petty F et al. (1998) Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry, 44: 98-106.
43. Hamid S, Dawe GS, Gray JA et al. (1997) Nicotine induces long-lasting potentiation in the dentate gyrus of nicotine-primed rats. Neurosci Res, 29: 81-85.
44. Hellström-Lindahl E, Mousavi M, Ravid R et al. (2004) Reduced levels of beta 40 and beta 42 in brains of smoking controls and Alzheimer's patients. Neurobiol Dis, 15: 351-360.
45. Hesse M (2002) Alkoloids. Nature's curse or blessing ((Çev. A. Beard). Wiley-VCH Press, Ochsenfurt-Hohestadt, s. 358-365.
46. Hughes JR, Hatsukami DK, Mitchell JE et al. (1986) Prevalence of smoking among psychiatric outpatients. Am J Psychiatry, 152: 993-997.
47. Jann MW, Saklad SR, Ereshefsky L et al. (1986) Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl), 90: 468-470.
48. Janson AM, Fuxe K, Agnati LF et al. (1989) Protective effects of chronic nicotine treatment on lesioned nigrostrital dopamine neurons in the male rat. Prog Brain Res, 79: 257-265.
49. Jones GMM, Sahakian BJ, Levy R et al. (1992) Effects of acute subcutaneous nicotine on attention, information processing and short term memory in Alzheimer's disease. Psychopharmacology, 108: 485-494.
50. Kalivas PW, Stewart J (1991) Dopamine transmission in the initiation of and expression of drug-and stress-induced sensitization of motor activity. Brain Res Rev, 16: 223-244.
51. Lai C, Hong C, Tsai S (2001) Association study of a nicotinic receptor variant with schizophrenic disorders. Neuropsychobiology, 43: 15-18.
52. Larrison-Faucher AL, Matorin AA, Sereno AB (2004) Nicotine reduces antisaccade errors in task impaired schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry, 28: 505-516.
53. Leonard S, Adler LE, Benhammou K et al. (2001) Smoking and mental illness. Pharmacol Biochem Behav, 70: 561-570.
54. Levin ED, Wilson W, Rose JE et al. (1996) Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology, 15: 429-436.
55. Lohr JB ve Flynn K (1992) Smoking and schizophrenia. Schizophr Res, 8: 93-102.
56. Longstreth WT, Arnold AM, Manolio, TA et al. (2000) Clinical correlates of ventricular and sulcal size on cranial magnetic resonance imaging of 3,301 elderly people: The cardiovascular health study. Collaborative Research Group. Neuroepidemiology, 19: 30-42.
57. Longstreth WT, Diehr P, Manolio TA, et al. (2001) Cluster analysis and patterns of findings on cranial magnetic resonance imaging of the elderly: The cardiovascular health study. Arch Neurology, 58: 635-640.
58. Lyon ER (1999) A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv, 50: 1346-50.
59. MacDermott AB, Role LW, Siegelbaum SA (1999) Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci, 22: 443-485.
60. Martin-Ruiz CM, Haroutunian VH, Long P et al. (2003) Dementia rating and nicotinic receptor expression in prefrontal cortex in schizophrenia. Biol Psychiatry, 54: 1222-1233.
61. McEvoy JP, Freudenreich O, Wilson WH (1999) Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry, 46: 125-129.
62. Mendez D, Warner KE (2004) Adult cigarette smoking prevalence: declining as expected (Not as desired). Am J Public Health, 94: 251-252.
63. Mihailescu S, Palomero-Rivero M, Meade-Huerta P et al. (1998) Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol, 360: 31-36.
64. Mihailescu S, Drucker-Colin R (2000) Nicotine, brain nicotinic receptors and neuropsychiatric disorder. Arch Med Res, 31: 131-144.
65. Mori T, Sasaki T, Iwanami A et al. (2003) Smoking habits in Japanese patients with schizophrenia. Psychiatry Res, 120: 207-209.
66. Mortensen PB, Juel K (1993) Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatr, 163: 183-189.
67. Newhouse PA, Sunderland T, Tariot PN et al. (1988) Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharmacology (Berl), 95: 171-175.
68. Newhouse PA, Potter A, Corwin J et al. (1992) Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology (Berl), 108: 480-484.
69. Newhouse PA, Potter A, Lenox RH et al. (1993) Effects of nicotinic agents on human cognition: Possible therapeutic applications in Alzheimer's and Parkinson's diseases. Med Chem Res, 2: 628-642.
70. Newhouse PA, Potter A, Corwin J et al. (1994) Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology, 10: 93-107.
71. Newhouse PA. Potter A, Corwin J et al. (1996) Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease. Drug Dev Res, 38: 278-289.
72. Newhouse PA, Potter A, Kelton M et al. (2001) Nicotinic treatment of Alzheimer's disease. Biol Psychiatry, 49: 268-278.
73. Newhouse PA, Potter A, Singh A (2004) Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol, 4: 36-46.
74. O'Farrell TJ, Conners GJ, Upper D (1983) Addictive behaviors among hospitalized schizophrenic patients. Addict Behav, 8: 329-333.
75. Olincy A, Ross RG, Roath M et al. (1998) Smooth pursuit eye movements and cigarette smoking in schizophrenia. Neuropsychopharmacology, 18: 175-185.
76. Olincy A, Johnson L, Ross R (2003) Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res, 117: 223-236.
77. Ögel K, Tamar D, Evren C et al. (2001) Tobacco, Alcohol and Drug Use Among High School Students. Turkish Journal of Psychiatry, 12: 47-52.
78. Ögel K, Tamar D, Özmen E et al. (2003) The prevalence of tobacco use in İstanbul sampling. Journal of Dependence, 4: 105-108.
79. Perry EK, Morris CM, Court JA et al. (1995) Alteration in nicotine binding sites Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience, 64: 385-395.
80. Picciotto MR, Zoli M, Lena C et al. (1998) Acetylcholine receptors containing the beta-2 subunit are involved in the reinforcing properties of nicotine. Nature, 391: 173-177.
81. Poirier MF, Canceil O, Bayle F et al. (2002) Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry, 26: 529-537.
82. Pontieri FE, Tanda G, Orzi F et al. (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 382: 255-257.
83. Rezvani AH, Levin ED (2001) Cognitive effects of nicotine. Biol Psychiatry, 49: 258-67.
84. Rezvani AH, Levin ED (2004) Nicotine antipsychotic drug interactions and attentional performance in female rats. Eur J Pharmacol, 486: 175-182.
85. Sahakian BJ, Coull JT (1994) Nicotine and THA: Evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res, 31: 80-88.
86. Salas R, Pieri F, Dani JA et al. (2003) Altered anxiety-related responses in mutant mice lacking the beta4 subunit of nicotinic receptor. J Neurosci, 23: 6255-6263.
87. Salin-Pascual R, Drucker-Colin R (1998) A novel effect of nicotine on mood and sleep in major depression Neuroreport, 9: 57-60.
88. Salokangas RK, Saarijarvi S, Taiminen T et al. (1997) Effect of smoking on neuroleptics in schizophrenia. Schizophr Res, 23: 55-60.
89. Sandyk R, Kay SR (1991) Tobacco addiction as a marker of age at onset of schizophrenia. Int J Neurosci, 57: 259-262.
90. Schwartz RD (1986) Autoradiographic distribution of high affinity muscarinic and nicotinic cholinergic receptors labelled with [3H] acetylcholine in rat brain. Life Sci, 38: 2111-2119.
91. Sneadal J, Johannesson T, Jonsson JE et al (1996) The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia, 7: 47-52.
92. Stancampiano R, Cocco S, Cugusi C et al. (1999) Serotonin and acetylcholine release response in the rat hippocampus during a spatial memory task. Neuroscience, 89: 1135-1143.
93. Taiminen TJ, Salokangas RKR, Saarijarvi S et al. (1998) Smoking and cognitive deficits in schizophrenia: A pilot study. Addict Behav. 23: 263-266.
94. Tsushima Y, Tanizaki Y, Aoki J et al. (2002) MR detection of microhemorrhages in neurologically healthy adults. Neuroradiology, 44: 31-36.
95. Uhl GR (1999) Neurochemical bases of drug abuse. Basic neurochemistry, molecular, cellular, and medical aspects, 6. baskι, GJ Siegal, BW Agranoff, AR Wayne, SK Fisher, MD Uhler (Ed), New York, Lippincott Williams and Wilkins, s. 1095-1109.
96. Uzun Ö. Cansever A, Basoǧlu B et al. (2003) Smoking and substance abuse in outpatients with schizophrenia: A 2-year follow-up study in Turkey. Drug Alcohol Depend, 70: 187-192.
97. Üçok A, Polat A, Bozkurt O et al. (2001) Smoking in patients with bipolar mood disorder and schizophrenia: A controlled study. Journal of Psychiatry Psycology Psychopharmacology, 2: 193-198.
98. Vazquez J, Guzman-Marin R, Salin-Pascual R et al. (1996) Transdermal nicotine on sleep and PGO spikes. Brain Res, 737: 317-320.
99. Volkow ND, Fowler JS, Ding YS et al. (1999) Imaging the neurochemistry of nicotine actions: Studies with positron emission tomography. Nicotine Tob Res, 1 (Suppl. 2): S127-S132.
100. White HK, Levin ED (1999) Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology (Berl) 143: 158-165.
101. WHO Regional Office for Europe (1997) Smoking, drinking and drug taking in the European region. Copenhagen.
102. Wilson AL, Langley LK, Monley J et al. (1995) Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety. Pharmacol Biochem Behav, 51: 509-514.
103. Wise RA, Gardner EL (2002) Functional neuroanatomy of substance related disorders. Biological Psychiatry, cilt 1, H D'haenen, den Boer, P Willner (Ed). Cornwall, John Wiley & Sons, s. 509-522.
104. Yildiz M, Özcan ME (2000) Prevalence of nicotine dependence in psychiatric outpatients. Journal of Dependence, 1: 86-88.
105. Zammit S, Allebeck P, Dalman C et al. (2003) Investigating the association between cigarette smoking and schizophrenia in a cohort study. Am J Psychiatry, 160: 2216-2221.
106. Ziedonis DM, Kosten TR, Glazer WM et al. (1994) Nicotine dependence and schizophrenia. Hosp Com Psychiatry, 45: 204-206.
107. Ziedonis DM, George TP (1997) Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull, 23: 247-254.
108. Zubieta J, Lomberdi U, Minoshima S et al. (2001) Regional blood flow effects of nicotine in overnight abstinent smokers. Biol Psychiatry, 49: 906-913.